Lilly Asia Ventures has returned to back the immuno-oncology therapy developer’s latest round, eight months after participating in the company’s series B.
US-based small molecule cancer drug developer NiKang Therapeutics secured $200m in series C funding yesterday from investors including Lilly Asia Ventures, a corporate venturing vehicle for pharmaceutical firm Eli Lilly.
Hedge fund manager Cormorant Asset Management and healthcare investment firms HBM Healthcare Investments and Octagon Capital co-led the round with Lilly Asia Ventures.
Ally Bridge Group, EcoR1 Capital, Invus, Janus Henderson Investors, Logos Capital, Pavilion Capital and funds and accounts managed by BlackRock took part, as did Perceptive Advisors, PFM…
